Beam Therapeutics Inc Aktie News
23,80 $
3,92 %
gestern
Nasdaq,
30. Oktober, 21:14 Uhr
tracken
Beam Therapeutics Inc Aktie News
Positiv
Seeking Alpha
●
8 Tage alt
Beam Therapeutics Inc.'s base editing platform with BEAM-101 have trait-like hematology and RMAT/ODD designations. BEAM thinks this could eventually position it with a potential best-in-class SCD drug. BEAM-302 also has a durable, dose-dependent AAT restoration. Similarly, BEAM-301 adds a second in-vivo liver shot, which I believe is another validator for their human platform.
Positiv
Schaeffers Research
●
23 Tage alt
Subscribers to Chart of the Week received this commentary on Sunday, October 5.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Beam Therapeutics Inc. (NASDAQ:BEAM ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 10:30 AM EDT Company Participants John Evans - CEO & Director Conference Call Participants Patrick Trucchio - H.C.
Neutral
Seeking Alpha
●
etwa 2 Monate alt
Beam Therapeutics Inc. (NASDAQ:BEAM ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants John Evans - CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President All right. Good afternoon.
Neutral
GlobeNewsWire
●
2 Monate alt
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference on Wednesday, September 3, 2025, at 4:00 p.m.
Neutral
GlobeNewsWire
●
3 Monate alt
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for ...
Neutral
GlobeNewsWire
●
3 Monate alt
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
